This is a working overview of somatotroph, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Measured responses usually involve growth hormone and insulin-like growth factor 1, known as IGF-1. Growth hormone rises in bursts and is difficult to sample reliably, while IGF-1 shifts more slowly and can be assessed from a single blood draw. Studies therefore treat IGF-1 as the more practical pharmacodynamic marker. Both are indirect, showing that the receptor was engaged rather than that the peptide reached a particular concentration. Direct exposure measurement requires an assay aimed at the molecule itself.
Published work tends to frame tesamorelin as a tool for studying the GHRH axis and as a compound with measurable effects on body composition. Reports often describe visceral adipose tissue as an endpoint, assessed by imaging rather than by inference. Analytical sections commonly describe liquid chromatography with tandem mass spectrometry to confirm identity and purity, because immunoassays may cross-react with related fragments. Where results diverge between studies, differences in assay choice, sampling timing, and population are frequent explanations offered. Whether effects persist after treatment stops remains an open question.
| Property | Value | Notes |
|---|---|---|
| Primary target | Growth hormone-releasing hormone receptor | Located on anterior pituitary somatotroph cells. |
| Receptor class | G protein-coupled receptor | Activation increases intracellular cyclic AMP. |
| Main downstream hormone | Growth hormone and insulin-like growth factor 1 | Growth hormone release precedes IGF-1 elevation. |
| Primary studied effect | Reduction in visceral adipose tissue | Measured by computed tomography in clinical trials. |
| Approximate half-life | 26–38 minutes after subcutaneous administration | Values vary by assay and study population. |
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Measuring the effect of a growth hormone-releasing hormone analogue requires markers that reflect pituitary output rather than the peptide itself. The two most frequently used are growth hormone and insulin-like growth factor 1. Growth hormone fluctuates sharply across the day and responds to sleep, stress, and meals, so isolated readings can be difficult to interpret. Insulin-like growth factor 1 changes more slowly and is often treated as the more stable integrated marker of axis activity.
Because growth hormone is released in pulses, single measurements can misrepresent overall secretion. Investigators sometimes use repeated sampling or overnight profiles to capture the pattern rather than a single value. Provocative testing, in which a stimulus is given and the response is tracked over time, offers another way to characterize the axis. Each approach carries trade-offs between sensitivity, burden on the participant, and the influence of non-target variables.
Insulin-like growth factor 1 is produced largely in the liver in response to growth hormone signaling. Its concentration shifts over days rather than minutes, which makes it practical for tracking changes across a study period. Interpretation still depends on age, nutritional status, and concurrent illness, all of which independently affect the marker. Reference ranges are therefore stratified, and comparisons are usually made within an individual over time rather than against a single population threshold.
==== Australian plate ==== Lord Howe hotspot (22) 34°42′S 159°48′E, w= 0.8 az= 351° ±10° Tasmantid hotspot (39) 40°24′S 155°30′E, w= 0.8 az= 007° ±5° rate= 63 ±5 mm/yr East Australia hotspot (30) 40°48′S 146°00′E, w= 0.3 az= 000° ±15° rate= 65 ±3 mm/yr
== Legal status == In the United States, chloral hydrate is a schedule IV controlled substance and requires a physician's prescription. Its properties have sometimes led to its use as a date rape drug. The phrase, "slipping a mickey," originally referred specifically to adding chloral hydrate to a person's (alcoholic) drink without the person's knowledge.
However, the experimental chemistry of meitnerium has not received as much attention as that of the heavier elements from copernicium to livermorium. Lawrence Berkeley National Laboratory tried to synthesize 271Mt in 2002–2003 for a possible chemical investigation of meitnerium, as it was expected that it might be more stable than nearby isotopes due to having 162 neutrons, a magic number for deformed nuclei; its half-life was predicted to be a few seconds, long enough for a chemical investigation. However, no atoms of 271Mt were detected; this isotope of meitnerium is currently unknown. An experiment determining the chemical properties of a transactinide would need to compare a compound of that transactinide with analogous compounds of some of its lighter homologs: for example, in the chemical characterization of hassium, hassium tetroxide HsO4 was compared with the osmium analog, osmium tetroxide OsO4. In a preliminary step toward determining the chemical properties of meitnerium, the GSI attempted sublimation of rhodium(III) oxide Rh2O3 and rhodium(III) chloride RhCl3. However, macroscopic amounts of the oxide would not sublimate until 1000°C and the chloride would not until 780°C, and then only in the presence of carbon aerosol particles: these temperatures are far too high for such procedures to be used on meitnerium, as most of the current methods used for the investigation of the chemistry of superheavies do not work above 500°C.
This local processing is especially important in image processing, where the early CNN layers typically identify simple local patterns such as edges and curves, with subsequent layers detecting more complex patterns like textures, and eventually whole objects.
Sources: en.wikipedia.org
Alton Meister (1922–1995) was an American biochemist who made pioneering contributions to the study of glutathione metabolism. Alton Meister was born in New York City to Morris Meister and Florence Glickstein Meister. He received an undergraduate degree from Harvard University and an MD from Cornell University Medical College (now Weill Cornell Medical College). He then moved to the National Cancer Institute at the National Institutes of Health in Bethesda, Maryland. He remained there until 1955 when he became Chairman of the Department of Biochemistry at Tufts University. Meister returned to Cornell University Medical College in 1967 and served as chairman of its biochemistry department until 1991. He died in 1995 at the age of 72.
In February 2022, Castillo held a bilateral meeting with then Brazilian president Jair Bolsonaro in Porto Velho. Although Bolsonaro, who was politically right-wing, harshly criticized Castillo's victory in 2021, after the meeting the Brazilian president assured that the differences had been overcome, that what had previously been declared had been forgotten, stating that Castillo was a defender of liberty and "conservative values", and that both countries would work to maintain a good relationship. The foreign ministries of both countries issued a joint statement agreeing to strengthen relations between both nations and reinforce the "strategic alliance".
Alamethicin is a channel-forming peptide antibiotic, produced by the fungus Trichoderma viride. It belongs to peptaibol peptides which contain the non-proteinogenic amino acid residue Aib (2-aminoisobutyric acid). This residue strongly induces formation of alpha-helical structure. The peptide sequence is
Sources: en.wikipedia.org
Radicalized by recent events, Polish reformers (whether in exile or still resident in the reduced area remaining to the Commonwealth) were soon working on preparations for a national insurrection. Tadeusz Kościuszko, a popular general and a veteran of the American Revolution, was chosen as its leader. He returned from abroad and issued Kościuszko's proclamation in Kraków on March 24, 1794. It called for a national uprising under his supreme command. Kościuszko emancipated many peasants in order to enroll them as kosynierzy in his army, but the hard-fought insurrection, despite widespread national support, proved incapable of generating the foreign assistance necessary for its success. In the end, it was suppressed by the combined forces of Russia and Prussia, with Warsaw captured in November 1794 in the aftermath of the Battle of Praga.
Cristalino [kɾistaˈlino] ("crystalline"): aged tequila that has been filtered to remove its color before bottling, similar to chill filtering of whisky Rosa ("pink"): a young version of the spirit "lightly aged in red wine barrels"
==== Microspheres ==== An aqueous suspension of progesterone encapsulated in microspheres is marketed for use by intramuscular injection under the brand name ProSphere in Mexico. It is administered once weekly or once monthly, depending on the indication. For instance, the medication is administered at a dose of 100 to 300 mg by intramuscular injection once every 7 days for the treatment of threatened miscarriage. The microspheres range in size from 33 to 75 μg and are delivered using pre-filled syringes with a 20-gauge 38 mm needle. Peak levels of progesterone after a single 100 or 200 mg intramuscular injection of ProSphere occur after about 1.5 days. The elimination half-life of progesterone with this formulation is about 8 days. A single 200 mg intramuscular injection maintains progesterone levels of more than 10 ng/mL for 5 to 7 days. ProSphere is well tolerated in terms of injection site reactions. A combination of both estradiol and progesterone encapsulated within microspheres as an aqueous suspension for use by intramuscular injection has been marketed under the brand name Juvenum in Mexico. Studies of this formulation have been published. Estradiol and progesterone encapsulated in microspheres has been studied for use as a once-a-month combined injectable contraceptive but has not been further developed nor introduced for medical use.
The diploid nature of chromosomes allows for genes on different chromosomes to assort independently or be separated from their homologous pair during sexual reproduction wherein haploid gametes are formed. In this way new combinations of genes can occur in the offspring of a mating pair. Genes on the same chromosome would theoretically never recombine. However, they do, via the cellular process of chromosomal crossover. During crossover, chromosomes exchange stretches of DNA, effectively shuffling the gene alleles between the chromosomes. This process of chromosomal crossover generally occurs during meiosis, a series of cell divisions that creates haploid cells. Meiotic recombination, particularly in microbial eukaryotes, appears to serve the adaptive function of repair of DNA damages. The first cytological demonstration of crossing over was performed by Harriet Creighton and Barbara McClintock in 1931. Their research and experiments on corn provided cytological evidence for the genetic theory that linked genes on paired chromosomes do in fact exchange places from one homolog to the other. The probability of chromosomal crossover occurring between two given points on the chromosome is related to the distance between the points. For an arbitrarily long distance, the probability of crossover is high enough that the inheritance of the genes is effectively uncorrelated. For genes that are closer together, however, the lower probability of crossover means that the genes demonstrate genetic linkage; alleles for the two genes tend to be inherited together.
Sources: en.wikipedia.org
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Binding stimulates cyclic AMP signaling and growth hormone secretion. This is the same receptor used by endogenous GHRH.
It does not act directly on adipose tissue as a primary mechanism. Instead, it increases endogenous growth hormone, which then influences lipolysis and fat distribution. The reduction in visceral fat is an indirect pharmacodynamic effect.
Tesamorelin acts upstream at the pituitary to amplify natural pulsatile growth hormone release. Growth hormone injections provide exogenous hormone and bypass pituitary regulation. The two approaches therefore differ in feedback control and hormonal dynamics.
It acts on the growth hormone–releasing hormone receptor, a Gs-coupled receptor found on pituitary somatotroph cells. Activation raises cAMP and prompts pulsatile hormone release.